Adaptimmune Therapeutics PLC — Director's Dealing 2025

Sep 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2025-09-02

Reporting Person: Wood Gavin (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-09-02	Ordinary Shares with a nominal value of GBP0.001 per share	S	96000	$0.0099	Disposed	0	Direct

Footnotes

F1: The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.

F2: The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs.

F3: The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

F4: The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer.